Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last

Summary

The headline reports a Q&A with Ryan Last on reshoring pharma and biotech manufacturing ahead of tariff deadlines this summer.

Why It Matters

For operators, the tariff deadlines make production location and sourcing decisions more time-sensitive. Investors and supply chain teams would assess whether reshoring changes cost exposure, capacity allocation, and reliance on overseas supply.